IOncology

In December 2024 a publication in the Annals of Surgical Oncology analyzed data from the National Cancer Database, showing that HER2 IHC3+ patients had significantly higher pathologic complete response (pCR)…

In the pursuit of improving outcomes for patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC), Dr. Filippo Pietrantonio has made significant contributions through groundbreaking research exploring the potential of combining vorbipiprant, a prostaglandin EP4 antagonist, with PD-1 blockade therapy.

This real-world study sheds light on the clinical outcomes of patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI). Conducted across Spain and Italy, the study evaluated 26 patients, offering valuable insights into survival outcomes and treatment-related adverse events in routine clinical practice.

The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.

Editor's Note: The European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. At this prestigious conference, Dr. Yanhong Deng from the Sixth Affiliated Hospital, Sun Yat-sen…

Editor's Note: Enhanced Recovery After Surgery (ERAS) has become a core concept in modern perioperative management. By implementing a series of evidence-based optimization measures, ERAS aims to reduce or mitigate…

The 2024 Annual Progress Conference on Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) was held in Guangzhou. Since 2015, the highly anticipated Annual Progress…

Editor's Note: Since the German scientist Paul Ehrlich introduced the concept of the "magic bullet" in 1913, antibody-drug conjugates (ADCs) have revolutionized cancer treatment, leading to significant breakthroughs and providing…

The MORPHEUS Phase Ib/II trial explores a transformative approach in clinical research by integrating real-world data (RWD) as a hybrid control arm to supplement traditional randomized controlled trials (RCTs) in pancreatic ductal adenocarcinoma (PDAC).

A recent publication in Diagnostics delves into the critical comparison between two cutting-edge molecular techniques—Methyl-BEAMing and Droplet Digital PCR (ddPCR)—for detecting MGMT gene promoter hypermethylation. This biomarker plays a pivotal role in various cancers, particularly glioblastomas, as it helps predict patient response to alkylating agent-based chemotherapy.